Monte Rosa Therapeutics (GLUE) Current Assets (2020 - 2026)

Monte Rosa Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $677.5 million for Q1 2026.

• In Q1 2026, Current Assets rose 103.91% year-over-year to $677.5 million; the TTM figure through Mar 2026 stood at $677.5 million (up 103.91% YoY), while the FY2025 annual figure was $393.2 million, up 4.17% from the prior year.
• Current Assets was $677.5 million for Q1 2026 at Monte Rosa Therapeutics, up from $393.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $677.5 million in Q1 2026 to a low of $182.9 million in Q3 2023.
• Historically, Current Assets has averaged $309.8 million across 5 years, with a median of $295.2 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Current Assets sank 38.05% in 2023, then soared 103.91% in 2026.
• A 5-year view of Current Assets shows it stood at $275.9 million in 2022, then slipped by 14.38% to $236.2 million in 2023, then jumped by 59.79% to $377.4 million in 2024, then gained by 4.17% to $393.2 million in 2025, then surged by 72.32% to $677.5 million in 2026.
• The last three Current Assets figures came in at $677.5 million (Q1 2026), $393.2 million (Q4 2025), and $401.8 million (Q3 2025), per Business Quant data.